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Abstract
Background: Increased platelet aggregation is implicated in the pathogenesis of ischemic stroke and anti-platelet
strategy may contribute to its therapy. Panaxatriol saponin (PTS), the main components extracted from Panax
notoginseng, has been shown to be efficacious in the prevention and treatment of ischemic stroke in China.
The aim of this study is to determine the anti-platelet activity and explore the underlying mechanisms.
Methods: Inhibitory effect of PTS and its main ginsenosides on agonists-induced platelet aggregation was determined
using rabbit or human platelets. Intracellular Ca2+ concentration ([Ca2+]i) mobilization was detected with fura-2/AM
probe. MAPKs phosphorylation was determined by Western blotting.
Results: Our results showed PTS inhibited the rabbit platelet aggregation induced by various agonists (collagen,
thrombin and ADP). The three main ginsenosides (Rg1, Re and R1) existing in PTS also showed anti-platelet activity,
while their combination exhibited no synergistic effect on rabbit platelet aggregation. Further study demonstrated that
PTS and its main ginsenosides also exhibited inhibitory effect on human platelet aggregation. Mechanism study
demonstrated that pre-treatment with PTS inhibited the agonists-induced intracellular calcium mobilization. Moreover,
PTS significantly suppressed the activation of both ERK2 and p38 by the agonists via reducing the phosphorylation of
ERK2 and p38.
Conclusion: We proved that PTS is effective in anti-platelet aggregation, which may, at least in part, be related to the
suppression of intracellular calcium mobilization and ERK2/p38 activation. This study may provide one reasonable
explanation for the efficacy of PTS on the prevention and treatment of ischemic stroke.
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Background
Platelets which only exist in mammals mainly function
as stopping bleeding at the site of interrupted endothe-
lium. Under normal physiological condition, platelets are
quiescent and don’t bind to fibrinogen. Once there is an
injury in the endothelium, platelets will adhere to the inter-
rupted endothelium and become activated via changing
shape, turning on receptors and secreting chemical
messengers. Then, they interconnect through receptor
bridges to form aggregation and finally promote the
blood coagulation [1]. However, abnormal platelet acti-
vation triggered by pathophysiological factors can lead
to the development and progression of vascular diseases
[2]. Increased platelet aggregation is believed to play an
important role in the pathogenesis of ischemic stroke
[3]. Therefore, anti-platelet therapy may represent an
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Panaxatriol saponin (PTS) is one of the major compo-
nents of Panax notoginseng and composed of ginseno-
side Rg1 (Rg1), notoginsenoside R1 (R1) and ginsenoside
Re (Re). It has been clinically used in China for the treat-
ment of cerebral infarction. Previous pharmacological
study demonstrated that PTS alleviated the focal cerebral
ischemia-induced injury via reducing the cerebral edema,
up-regulating HSP70 expression and down-regulating
transferring [4]. Our recent investigation indicated that
PTS exerted neuroprotection through modulating the
cyto-protective Nrf2 signaling pathway [5]. In addition,
several studies have reported that ginsenosides, for ex-
ample, Rp1 [6], Rg3 [7], Rg1 [8], Rh1 and F1 [9], exhibited
the anti-platelet activities. In view of the protective effect
on ischemic stroke, whether PTS also has the anti-platelet
activity is accordingly drawing our attention. Therefore,
we designed experiments to investigate the effect of PTS
on platelet aggregation and explore the underlying mecha-
nisms in the current study.
Methods
Materials
PTS extracted from Panax notoginseng was obtained from
Huasun Group Co., Ltd. (Sichuan, China). As determined
in our previous study [5], PTS is comprised of Rg1, R1
and Re with the concentration of 46.1, 12.3 and 5.7 %, re-
spectively. The antibodies against p-ERK, p-p38 and HRP
conjugated goat anti-mouse IgG were purchased from Cell
Signaling Technology (Boston, MA, USA). Thrombin and
collagen were purchased from Sigma-Aldrich (St. Louis,
MO, USA). ADP was obtained from Tokyo Chemical
Industry (Shanghai) Co. Ltd. (Shanghai, China). Fura-2/
AM was obtained from Beyotime Biotechnology Corpor-
ation (Jiangsu China). Other chemicals were obtained from
Sigma-Aldrich Co. (St. Louis, MO, USA) unless indicated
otherwise. Human peripheral blood was collected from
healthy human donors after obtaining the informed con-
sent under a Chengdu University of Traditional Chinese
Medicine Internal Review Board–approved protocol.
Experimental animals
New Zealand albino rabbits (2.0 ± 0.2 kg) used in this
study were obtained from Experimental Animal Center
of Chengdu University of Traditional Chinese Medicine.
The animals were acclimated for 1 week prior to the ex-
periments, and housed in an air-conditioned animal
room with a 12/12 h light/dark cycle at a temperature of
25 ± 1 °C and humidity of 50 ± 10 %. The animals were
provided with a laboratory diet and water ad libitum. All
experimental protocols involving the use of animals were
conducted in accordance with National Institutes of
Health (NIH) guidelines and approved by the Committee
on Animal Care at the Southwest University.
Platelet preparation
The preparation of the platelets has been described pre-
viously with minor modifications [6]. The human blood
or rabbit blood was transferred to a tube containing
1 ml of a citrate phosphate dextrose solution (90 mM
Na3C6H5O7 · 2H2O, 16 mM C6H8O7 · H2O, 16 mM
NaH2PO4 · H2O, 142 mM dextrose). Platelet-rich plasma
(PRP) was obtained by centrifuging rabbit blood samples
at 230 × g for 5 min. Platelets were precipitated by centri-
fugation of the PRP at 800 × g for 15 min and washed
twice with the washing buffer (10 mM Na3C6H5O7 ·
2H2O,150 mM NaCl,1 mM EDTA,1 % (w/v) dextrose
and pH 7.4). The pellet was re-suspended in HEPES
buffer (140 mM NaCl, 2.7 mM KCl, 3.8 mM HEPES,
5 mM EGTA and pH 7.4) and the cell dilution was ad-
justed to 4 × 108 cells · ml-1 for subsequent experiment.
Platelet aggregation assay
Platelet aggregation was performed as previously de-
scribed [10]. Briefly, blank solvent and test samples at
various concentrations were added to 200 μl of PRP
and after 15 min aggregation was initiated by adding
different inducers in each well of 96-well plates, respect-
ively. Optical density (OD) at 630 nm was measured with
Microplate Reader (BioTek ELX800) after 1, 2, 4, 10 min
of the addition. All the experiments were performed in
triplicate. The platelet aggregation rate is expressed as
PAR (%) and calculated as follows:
PAR %ð Þ ¼ 1‐OD0ð Þ=OD1  100%
Whereas OD0 and OD1 indicate the optical density be-
fore and after the inducer is added, respectively.
The following equation is used to calculate the in-
hibition rate (IR) of platelet aggregation.
IR %ð Þ ¼ 1‐PARtestð Þ=PARblank  100%
Whereas PARtest and PARblank represent the PAR of
the tested samples and the blank solvent, respectively.
Determination of the intracellular calcium concentration
([Ca2+]i)
[Ca2+]i was determined with fura-2/AM as described
previously [6]. Briefly, the PRP with concentration of
4 × 108 cells/ml was incubated with 5 μM of fura-2/AM
for 60 min at 37 °C. The fura-2-loaded washed platelets
were pre-incubated with the tested sample or the blank
solvent (saline) for 3 min at 37 °C in the presence of
1 mM CaCl2. Next, the platelets were stimulated with
thrombin (0.1 U · ml-1), collagen (2.5 μg · ml-1) or ADP
(10 μM) for 5 min, respectively. Fura-2 fluorescence was
measured in a spectrofluorometer (F-2500, Hitachi,
Japan) with an excitation wavelength of 340 nm and an
emission wavelength of 510 nm. The [Ca2+]i was
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calculated by the method of Schaeffer [11]: [Ca2+]i in
cytosol = 224 nM×(F − Fmin)/(Fmax − F), where 224 nM is
the dissociation constant of the fura-2-Ca2+ complex,
and Fmin and Fmax represent the fluorescence intensity
levels at very low and very high Ca2+ concentrations, re-
spectively. In our experiment, Fmax is the fluorescence
intensity of the fura-2-Ca2+ complex at 510 nm after the
platelet suspension containing 1 mM of CaCl2 had been
solubilized by Triton X-100 (0.1 %). Fmin is the fluores-
cence intensity of the fura-2-Ca2+ complex at 510 nm,
after the platelet suspension containing 20 mM Tris/
3 mM of EGTA had been solubilized by Triton X-100
(0.1 %). F represents the fluorescence intensity of the
fura-2-complex at 510 nm after the platelet suspension
was stimulated by inducer, with and without the tested
samples, in the presence of 1 mM CaCl2.
Western blotting analysis
The cellular proteins were extracted and analyzed for
protein expression as previously described [12]. Briefly,
thirty micrograms of the cellular proteins were resolved
by electrophoresis in 10 % SDS-polyacrylamide gel, and
subsequently transferred to polyvinylidene difluoride
(PVDF) membrane. Following 1 h incubation in a fresh
TBS buffer containing 0.1 % Tween-20 and 5 % BSA,
the blots were probed with specific antibodies including
anti-p-ERK, anti-p-p38 and anti-β-actin. The bound pri-
mary antibodies were detected by HRP conjugated anti-
mouse IgG accordingly. The activity of peroxidase on
the blot was visualized by enhanced chemiluminescence
(ECL) detection reagents (GE Healthcare, Sweden).
Statistical analysis
All data were presented as mean ± SD from three inde-
pendent experiments. Statistical analysis was performed
by two-tail Student’s t-test. A P-value of less than 0.05
was considered to be statistically significant.
Results
Inhibitory effect of PTS on agonist induced rabbit platelet
aggregation
To determine the effect of PTS on rabbit platelet aggre-
gation, we examined its anti-platelet activity against sti-
mulation of different agonists. washed platelets were
pre-incubated with different concentrations of PTS and
then exposed to collagen, thrombin and ADP, respectively.
As shown in Fig. 1a, PTS significantly inhibited the rabbit
platelet aggregation activated by collagen at the concen-
tration of 1, 3 and 10 mg · ml-1, with the inhibition rate of
63.9, 69.8 and 71.3 %, respectively. Figure 1b shows that
treatment of rabbit platelets with 3 and 10 mg · ml-1 PTS
markedly inhibited the aggregation induced by thrombin,
with the inhibition rate of 55.5 and 56.4 %, respectively.
Similarly, 3 and 10 mg ·ml-1 PTS also significantly inhibited
ADP-induced rabbit platelet aggregation with the inhibition
rate of 55.3 and 55.9 %, respectively.
Inhibitory effect of the main ginsenosides in PTS on
thrombin induced rabbit platelet aggregation
As PTS consists of three main ginsenosides (Rg1, Re and
R1), we are then interested in the effect of these single
compounds on rabbit platelet inhibition and asked
whether there is a synergistic effect when they are used as
a combination. As shown in Fig. 2a, Rg1 dose-dependently
inhibited the aggregation activated by thrombin within the
concentration of 10-100 μM. However, both Re and R1
only significantly inhibited the thrombin induced rabbit
platelet aggregation at 100 μM within the same tested con-
centration range (Fig. 2b and c). When these three com-
pounds were used together at the same concentration,
only the combination with 50 and 100 μM showed signifi-
cantly inhibitory activity on thrombin induced rabbit
platelet aggregation and there was no synergistic effect
observed.
Inhibitory effect of PTS and its main ginsenosides on
agonist induced human platelet aggregation
To further confirm the anti-platelet aggregation effect of
PTS and its main ginsenosides, we then determined
their inhibitory effect on human platelet aggregation. As
shown in Fig.3a, PTS significantly inhibited the human
platelet aggregation induced by collagen, thrombin and
ADP, respectively. Moreover, the three main ginseno-
sides (Rg1, Re and R1) also exhibited significant anti-
platelet aggregation effect against ADP-induced human
platelet aggregation (Fig.3b).
Effect of PTS on calcium mobilization
It’s well established that [Ca2+]i is critical for the activa-
tion and aggregation of platelet aggregation [13–15].
The decrease of [Ca2+]i directly inhibits the platelet ag-
gregation. Therefore, we determined the influence of
PTS on the calcium mobilization. Figure 4a showed that
thrombin alone markedly enhanced the [Ca2+]i. When
pre-incubation of platelets with various concentration of
PTS, the [Ca2+]i induced by thrombin dose-dependently
decreased by 58.2, 67.3 and 79.4 % at concentrations of
0.5, 1 and 3 mg · ml-1 (p < 0.05), respectively. Similarly,
Fig. 4b and c show that 1 and 3 mg · ml-1 of PTS signifi-
cantly reduced collagen-activated [Ca2+]i and 3 mg · ml
-1
of PTS significantly reduced ADP-activated [Ca2+]i.
Effect of PTS on the phosphorylation of MAPKs
Since MAPKs (ERK2, JNK1 and p38) are reported to be
present in platelets and involved in the action of numerous
anti-platelet agents [16], we determined whether thrombin
induced MAPKs phosphorylation is regulated as a sig-
naling pathway in the anti-platelet activity of PTS. As
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shown in Fig. 5a, PTS with 1 and 3 mg · ml-1 signifi-
cantly reduced the phosphorylation of ERK2 induced
by thrombin. Meanwhile, PTS with the concentrations
of 0.5-3 mg · ml-1 significantly reduced the phosphoryl-
ation of p38 induced by thrombin (Fig. 5b). Then, we
further determined the effect of PTS on the phosphor-
ylation of ERK2 and p38 induced by collagen and ADP,
respectively. Figure 5c and e show that the phosphoryl-
ation of ERK2 induced by collagen and ADP was sig-
nificantly reduced by PTS and Fig. 5d and f show that
the phosphorylation of p38 induced by collagen and
ADP was also significantly reduced by PTS.
Discussion
In this study, we first determined the inhibitory activity
of PTS on platelet aggregation activated by collagen,
thrombin and ADP, respectively. It’s well established that
the three different agonists act on different types of re-
ceptors. Collagen is a potent ligand against integrin-type
receptors, including α2β1 and glycoprotein VI, whereas
thrombin and ADP are potent ligands of G-protein
coupled seven transmembrane receptors (GPCR) (PAR-1
and PAR-4 thrombin receptors, P2Y1 and P2Y12 ADP re-
ceptors), respectively [17–19]. Our result demonstrated
that PTS showed anti-platelet activity irrelevant to the
types of agonists, suggesting that PTS may not function
as an antagonist to counteract the binding to platelet re-
ceptors on the plasma membrane of these three agonists.
PTS is a complex fraction containing three major ginse-
nosides Rg1, Re and R1 [5]. Previous study showed that
Rg1 [8] exhibited anti-platelet activity. Then, we are in-
terested to determining the effect of another two main
Fig. 1 Inhibitory effect of PTS on collagen, thrombin or ADP induced platelet aggregation. Platelets (4 × 108 cells · ml-1) were pre-incubated with
or without PTS and then stimulated with a collagen (2.5 μg · ml-1), b thrombin (0.1 U · ml-1) or c ADP (10 μM). The platelet aggregation rate and
the inhibition rate of platelet aggregation were determined. Bar graphs show mean ± SD of at least 3 independent experiments performed.
*p < 0.05 vs. agonist activated control
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compounds (Re and R1) in PTS on platelet aggregation
and whether the combination of these three ginsenosides
could function synergistically. As a result, Rg1 inhibited
the platelet aggregation at relative low concentrations,
whereas Re showed stronger effect at higher concentra-
tion. The inhibitory activity of R1 was much similar than
that of Re. However, the potency of the combination in
inhibiting platelet aggregation didn’t improve, indicating
there may be no synergistic effect among the compo-
nents in PTS. To make our study become more clinical
relevance, we then determined the effect of PTS and its
main ginsenosides on human platelet aggregation. As a
result, both PTS and its main ginsenosides showed sig-
nificant inhibitory effect.
[Ca2+]i plays an important role in the activation and
aggregation of platelets and the thrombus formation.
The exogenous or endogenous activation of a mem-
brane receptor with thrombin, collagen or ADP leads
to the influx of Ca2+ into the platelets [20, 21]. The ac-
tivation of thrombin receptors PAR1 and PAR4 or a
Fig. 3 Inhibitory effect of PTS and its main ginsenosides on human platelet aggregation. a Human platelets (4 × 108 cells · ml-1) were pre-incubated with
or without PTS and then stimulated with collagen (2.5 μg ·ml-1), thrombin (0.1 U · ml-1) or ADP (10 μM). The platelet aggregation rate was determined.
b Human platelets (4 × 108 cells · ml-1) were pre-incubated with or without Rg1, Re, R1, and then stimulated with ADP (10 μM). The platelet aggregation
rate was determined. Bar graphs show mean ± SD of at least 3 independent experiments performed. *p < 0.05, **p< 0.01 vs. agonist activated control
Fig. 2 Inhibitory effect of the main ginsenosides in PTS on thrombin induced platelet aggregation. Platelets (4 × 108 cells · ml-1) were pre-incubated
with or without Rg1 (a), Re (b), R1 (c) or their combination of equal concentration (d), and then stimulated with thrombin (0.1 U · ml-1). The platelet
aggregation rate was determined. Bar graphs show mean ± SD of at least 3 independent experiments performed. *p< 0.05 vs. agonist activated control
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P2Y ADP receptor, which belong to the Gq protein-
coupled receptors, leads to the activation of phospholipase
(PLC)-β. Additionally, collagen binds to glycoprotein
VI on the platelet surface leading to the increase of
PLC activity by phosphorylating PLCγ-2 on a tyrosine
residue. Then, these receptors stimulate the release of
inositol trisphosphate (IP3) from phosphatidylinositol
bisphosphate (PIP2). Finally, the calcium mobilization
is resulted by the binding of IP3 to type 2 IP3 receptors
in the secretory granules of human platelets [14, 22, 23].
To find out the possible signaling pathway involved in the
downstream of membrane receptors, we determined the
effect of PTS on the intracellular calcium mobilization. In
our study, all the three agonists thrombin, collagen and
ADP stimulate the [Ca2+]i. While pre-treatment with PTS,
the [Ca2+]i in all these agonists-activated platelets re-
markably reduced, suggesting that inhibition of calcium
mobilization may be one of the common signaling
pathways responsible for the inhibitory effect of PTS
against platelet aggregation stimulated by these three
different agonists.
MAPKs including ERK2, JNK1 and p38 are present in
platelets and activated by various agonists [16, 24]. Our
results demonstrated that PTS significantly suppressed
the activation of both ERK2 and p38 induced by throm-
bin, collagen or ADP via reducing the expression level of
p-ERK2 and p-p38. However, PTS showed no statisti-
cally significant influence on p-JNK1 (data not shown).
It’s reported that ERK2 and p38 have complementary ef-
fects in the control of platelet adhesion to collagen. In
static adhesion condition, p38 was involved in platelet
adhesion and spreading. In blood flow condition, p38 ac-
tivation is required for platelet adhesion at low collagen
coverage densities, while ERK2 activation is necessary
for platelet adhesion at higher collagen coverage densities
[16]. Therefore, suppression of ERK2 and p38 activation
may be partially as a common signaling pathway respon-
sible for the inhibitory effect of PTS on platelet aggrega-
tion in our study.
Conclusion
In summary, we have investigated the potential effect of
PTS on platelet aggregation and explored the underlying
Fig. 4 Effect of PTS on intracellular Ca2+ concentration ([Ca2+]i) in
thrombin, collagen or ADP activated platelets. Platelets were loaded
with Fura-2/AM as described in ‘Materials and Methods Section’. The
platelets (4 × 108 cells · ml-1) were pre-incubated with or without a
PTS and then the platelets were stimulated with thrombin (0.1 U/ml)
(a), collagen (2.5 μg · ml-1) (b) or ADP (10 μM) (c) for 5 min, respectively.
[Ca2+]i levels were determined as described in ‘Materials and Methods
Section’. Bar graphs show mean ± SD of at least 3 independent
experiments performed. *p <0.05 vs. agonist activated control
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mechanisms in this study. PTS exhibited anti-platelet
activity against stimulation of different agonists, includ-
ing collagen, thrombin and ADP. The three major gin-
senosides used alone also showed anti-platelet activity,
whereas their combination didn’t improve the effect
synergistically. Further mechanism study revealed that
PTS significantly inhibited intracellular calcium mo-
bilization induced by the three different agonists. More-
over, PTS also inhibited the phosphorylation of ERK2
and p38 induced by all the three agonists. Collectively,
our study showed PTS has anti-platelet activity and
inhibition of intracellular calcium mobilization and p-
ERK2/p-p38 may, in part, be as the common signaling
pathways responsible for this effect. The anti-platelet
activity of PTS may be implicated in its beneficial effect
on the prevention and treatment of ischemic stroke.
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